Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.

Kadidja Gamougam; Doumagoum M Daugla; Jacques Toralta; Cyriaque Ngadoua; Florence Fermon; Anne-Laure Page; Mamoudou H Djingarey; Dominique A Caugant; Olivier Manigart; Caroline L Trotter; James M Stuart; Brian M Greenwood

doi:10.3201/eid2101.140256

Publisher Website

Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.

Authors

Gamougam, Kadidja
Daugla, Doumagoum M
Toralta, Jacques
Ngadoua, Cyriaque
Fermon, Florence
Page, Anne-Laure
Djingarey, Mamoudou H
Caugant, Dominique A
Manigart, Olivier
Trotter, Caroline L
Stuart, James M
Greenwood, Brian M

Type

Published Article

Journal

Emerging Infectious Diseases

Publisher

Centers For Disease Control and Prevention

Publication Date

Jan 01, 2015

Volume

21

Issue

1

Pages

115–118

Identifiers

DOI: 10.3201/eid2101.140256

PMID: 25536336

Source

Medline

Language

English

License

Unknown

Abstract

In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated areas, but an epidemic continued in the rest of Chad. In 2012, the remaining Chad population was vaccinated, and the epidemic was halted.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 02/13/2022 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/25536336

Report this publication

Statistics

Seen <100 times